Imugene’s Chief Operating Officer, Leslie Chong, hails this milestone as a significant achievement in the clinical development of HER-Vaxx. "Within my experience of developing numerous world class oncology medicines it is truly remarkable to have all our sites’ Ethics Committee review applications completed and submitted within 7 weeksof finalising the study protocol. Reaching this major milestone so efficiently demonstrates the calibre of Imugene’s clinical development team and strategically places us well for a successful re-entry of Her-Vaxx into the clinic in 2016".
I am not a bio-expert but each of the previous medical anns got this extraordinary achievements compared to others mentioned. For how long will the BIO-investment world still ignore this gem ?
Time to buy more, its close to heat up I reckon.
IMU Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)